Patents by Inventor Jennifer Riggs

Jennifer Riggs has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11672776
    Abstract: Among other aspects, provided herein are multi-armed polymer conjugates comprising an alkanoate-linker, compositions comprising such conjugates, and related methods of making and administering the same. Methods of treatment employing such conjugates and related uses are also provided. The conjugates are prepared with high drug loading efficiencies.
    Type: Grant
    Filed: July 3, 2018
    Date of Patent: June 13, 2023
    Assignee: Nektar Therapeutics
    Inventors: Antoni Kozlowski, Samuel P. McManus, Jennifer Riggs-Sauthier, Xiaoming Shen, Wen Zhang
  • Patent number: 11674150
    Abstract: Products are provided that improve overall plant vigor and yield by combining agriculturally effective amounts of at least one spore-forming bacterium and at least one optional insect control agent to a genetically modified plant, plant part, or seed. This product is particularly effective in the presence of plant parasitic nematode and fungal species. Use of the product leads to an overall reduction in crop losses caused by either plant parasitic nematodes or fungi and this reduction is much greater than using genetically modified seed with just an insect control agent. According to some embodiments, the use of the product results in about a 2%-10% increase in soybean bushel yield, 3%-6.5% increase in cotton yield, and 3%-8% in corn bushel yield. Methods for utilizing and manufacturing the combination are also provided.
    Type: Grant
    Filed: September 9, 2015
    Date of Patent: June 13, 2023
    Assignee: BASF Corporation
    Inventor: Jennifer Riggs
  • Publication number: 20230119470
    Abstract: Provided herein are Heteroaryl Compounds having the following structure: wherein R1-R4 are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions, comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.
    Type: Application
    Filed: February 25, 2022
    Publication date: April 20, 2023
    Inventors: Jan ELSNER, Kimberly E. Fultz, Roy L. HARRIS, III, Branden Gingsee LEE, Loui Thomas Madakamutil, Deborah S. Mortensen, Rama Krishna Narla, Garrick K. PACKARD, Patrick PAPA, Jason PARNES, Sophie Perrin-Ninkovic, Jennifer RIGGS, Sabita SANKAR, John J. Sapienza, Graziella I. Shevlin, Lida Tehrani, Weiming XU, Jingjing ZHAO
  • Patent number: 11612662
    Abstract: Among other aspects, provided herein are multi-arm polymeric prodrug conjugates of pemetrexed-based compounds. Methods of preparing such conjugates as well as methods of administering the conjugates are also provided. Upon administration to a patient, release of the pemetrexed-based compound is achieved.
    Type: Grant
    Filed: June 25, 2020
    Date of Patent: March 28, 2023
    Assignee: Nektar Therapeutics
    Inventors: Lin Cheng, Jennifer Riggs-Sauthier
  • Patent number: 11464788
    Abstract: The invention provides corticosteroids that are chemically modified by covalent attachment of a water-soluble oligomer. A compound of the invention, when administered by any of a number of administration routes, exhibits a reduced biological membrane crossing rate as compared to the biological membrane crossing rate of the corticosteroid not attached to the water-soluble oligomer.
    Type: Grant
    Filed: October 19, 2017
    Date of Patent: October 11, 2022
    Assignee: Nektar Therapeutics
    Inventors: Wen Zhang, Jennifer Riggs-Sauthier, J. Milton Harris, Michael D. Bentley
  • Patent number: 11292796
    Abstract: Provided herein are Heteroaryl Compounds having the following structure: wherein R1-R4 are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions, comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof. Further provided herein are methods for preparing a compound of formula (I), the method comprising contacting a compound of formula (III) with a compound of the following formula: R1-Y, in a solvent, in the presence of a palladium catalyst, wherein said contacting occurs in the presence of a base, wherein R1-R4, Y, the palladium catalyst and the base are as defined herein.
    Type: Grant
    Filed: May 4, 2020
    Date of Patent: April 5, 2022
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Jan Elsner, Roy L. Harris, Branden Gingsee Lee, Deborah Mortensen, Garrick K. Packard, Patrick Papa, Jason Parnes, Sophie Perrin-Ninkovic, Jennifer Riggs, John Sapienza, Graziella I. Shevlin, Lida Tehrani, Jingjing Zhao
  • Publication number: 20220072010
    Abstract: The invention provides corticosteroids that are chemically modified by covalent attachment of a water-soluble oligomer. A compound of the invention, when administered by any of a number of administration routes, exhibits a reduced biological membrane crossing rate as compared to the biological membrane crossing rate of the corticosteroid not attached to the water-soluble oligomer.
    Type: Application
    Filed: November 16, 2021
    Publication date: March 10, 2022
    Inventors: Wen Zhang, Jennifer Riggs-Sauthier, J. Milton Harris, Michael D. Bentley
  • Patent number: 11140903
    Abstract: Provided are methods for reducing the occurrence of sudden death syndrome in plants, such as soybeans, using compounds of the general formula (I).
    Type: Grant
    Filed: May 7, 2018
    Date of Patent: October 12, 2021
    Assignee: Bayer CropScience LP
    Inventors: Jennifer Riggs, David Doran
  • Patent number: 11007270
    Abstract: The invention relates to (among other things) polymer-semaxanib moiety conjugates and related compounds. A compound of the invention, when administered by any of a number of administration routes, exhibits advantages over the semaxanib moiety in unconjugated form.
    Type: Grant
    Filed: October 3, 2019
    Date of Patent: May 18, 2021
    Assignee: Nektar Therapeutics
    Inventors: Jennifer Riggs-Sauthier, Stephanie Allums-Donald, Sean M. Culbertson
  • Patent number: 10959531
    Abstract: An enclosure for installation on a bed. The enclosure includes an enclosure-frame, an attachment-bracket, a foldable-board and a canopy. In some embodiments, the enclosure includes a power-supply, vents, fans, speakers and lights. The enclosure is useful for providing a user with a peaceful night sleep by preventing external noises and light from disrupting the user.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: March 30, 2021
    Inventors: Randall A. Riggs, Jennifer Riggs
  • Patent number: 10881738
    Abstract: The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits a different biological membrane crossing rate as compared to the biological membrane crossing rate of the small molecule drug not attached to the water-soluble oligomer.
    Type: Grant
    Filed: February 15, 2019
    Date of Patent: January 5, 2021
    Assignee: Nektar Therapeutics
    Inventors: Jennifer Riggs-Sauthier, Franco J. Duarte, Aaron S. Hammons
  • Patent number: 10869933
    Abstract: The invention relates to (among other things) oligomer-phenothiazine conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes, exhibits advantages over un-conjugated phenothiazine compounds.
    Type: Grant
    Filed: October 11, 2019
    Date of Patent: December 22, 2020
    Assignee: Nektar Therapeutics
    Inventors: Xuyuan Gu, Jennifer Riggs-Sauthier
  • Patent number: 10844076
    Abstract: The instant disclosure relates to (among other things) compounds that are derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine. The compounds provided possess unique effects and differences over other phenyltriazines known in the art.
    Type: Grant
    Filed: November 6, 2018
    Date of Patent: November 24, 2020
    Assignee: Nektar therapeutics
    Inventors: Pankaj Sharma, Vijay Kumar Khatri, Xuyuan Gu, Yuan Song, Michael Lixin Shen, Jennifer Riggs-Sauthier, Neel K. Anand, Antoni Kozlowski, Aleksandrs Odinecs, Timothy A. Riley, Zhongxu Ren, YongQi Mu, Xiaoming Shen, Xuejun Yuan, Natalia Aurrecoechea, Donogh John Roger O'Mahony, Bo-Liang Deng
  • Publication number: 20200323992
    Abstract: Among other aspects, provided herein are multi-arm polymeric prodrug conjugates of pemetrexed-based compounds. Methods of preparing such conjugates as well as methods of administering the conjugates are also provided. Upon administration to a patient, release of the pemetrexed-based compound is achieved.
    Type: Application
    Filed: June 25, 2020
    Publication date: October 15, 2020
    Inventors: Lin Cheng, Jennifer Riggs-Sauthier
  • Publication number: 20200305436
    Abstract: The disclosure provides for compositions and methods comprising clothianidin, a Bacillus-based compound or composition, a fungicide, and methods of uses thereof. Also provided are seeds and plants coated or treated with compositions described herein. The disclosure further provides for methods of reducing and/or delaying the resistance of a pest or pest population to one or more plant traits. Also provided for are compositions capable of reducing and/or delaying SCN resistance to one or more plant traits, by applying a composition described herein, for example, one or more compositions comprising clothianidin, a Bacillus firmus, and fluopyram to a seed, plant, and plant part.
    Type: Application
    Filed: June 5, 2017
    Publication date: October 1, 2020
    Inventors: Jennifer RIGGS, Michael McCARVILLE
  • Publication number: 20200262840
    Abstract: Provided herein are Heteroaryl Compounds having the following structure: wherein R1-R4 are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions, comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.
    Type: Application
    Filed: May 4, 2020
    Publication date: August 20, 2020
    Inventors: Jan ELSNER, Roy L. HARRIS, Branden Gingsee LEE, Deborah MORTENSEN, Garrick K. PACKARD, Patrick PAPA, Jason PARNES, Sophie PERRIN-NINKOVIC, Jennifer RIGGS, John SAPIENZA, Graziella I. SHEVLIN, Lida TEHRANI, Jingjing ZHAO
  • Patent number: 10736969
    Abstract: Among other aspects, provided herein are multi-arm polymeric prodrug conjugates of pemetrexed-based compounds. Methods of preparing such conjugates as well as methods of administering the conjugates are also provided. Upon administration to a patient, release of the pemetrexed-based compound is achieved.
    Type: Grant
    Filed: December 21, 2011
    Date of Patent: August 11, 2020
    Assignee: Nektar Therapeutics
    Inventors: Lin Cheng, Jennifer Riggs-Sauthier
  • Patent number: 10683298
    Abstract: Provided herein are Heteroaryl Compounds having the following structure: wherein R1-R4 are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions, comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.
    Type: Grant
    Filed: November 12, 2018
    Date of Patent: June 16, 2020
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Jan Elsner, Roy L. Harris, Branden Gingsee Lee, Deborah Mortensen, Garrick K. Packard, Patrick Papa, Jason Parnes, Sophie Perrin-Ninkovic, Jennifer Riggs, John Sapienza, Graziella I. Shevlin, Lida Tehrani, Jingjing Zhao
  • Publication number: 20200078353
    Abstract: The invention provides compounds that are chemically modified by covalent attachment of a water-soluble oligomer. A compound of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from those of the compound not attached to the water-soluble oligomer.
    Type: Application
    Filed: November 13, 2019
    Publication date: March 12, 2020
    Inventors: Jennifer Riggs-Sauthier, Bo-Liang Deng, Timothy A. Riley
  • Publication number: 20200038517
    Abstract: The invention relates to (among other things) oligomer-phenothiazine conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes, exhibits advantages over un-conjugated phenothiazine compounds.
    Type: Application
    Filed: October 11, 2019
    Publication date: February 6, 2020
    Inventors: Xuyuan Gu, Jennifer Riggs-Sauthier